SEC Comment Letter for vTv Therapeutics Inc. (VTVT) (CIK 0001641489) (VTVT) — Apr 16, 2024
vTv Therapeutics Inc. (VTVT) (CIK 0001641489)
Date: April 16, 2024 · CIK: 0001641489 · Accession: 0000000000-24-004105
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-278612
Letter
United States securities and exchange commission logo April 15, 2024 Steven Tuch Chief Financial Officer vTv Therapeutics Inc. 3980 Premier Drive, Suite 310 High Point, NC 27265 Re:vTv Therapeutics Inc. Registration Statement on Form S-3 Filed April 10, 2024 File No. 333-278612 Dear Steven Tuch: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: David Rosenthal, Esq.
Show Raw Text
United States securities and exchange commission logo
April 15, 2024
Steven Tuch
Chief Financial Officer
vTv Therapeutics Inc.
3980 Premier Drive, Suite 310
High Point, NC 27265
Re:vTv Therapeutics Inc.
Registration Statement on Form S-3
Filed April 10, 2024
File No. 333-278612
Dear Steven Tuch:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: David Rosenthal, Esq.